Literature DB >> 12127782

Species tropism of chimeric SHIV clones containing HIV-1 subtype-A and subtype-E envelope genes.

Sunee Himathongkham1, Gordon C Douglas, Adrienne Fang, Emily Yu, Susan W Barnett, Paul A Luciw.   

Abstract

To analyze HIV-1 genes in a nonhuman primate model for lentivirus infection and AIDS, recombinant SIV/HIV-1 (SHIV) clones were constructed from two HIV-1 subtype-A isolates (HIV-1(SF170) and HIV-1(Q23-17) from individuals in Africa) and two HIV-1 subtype-E isolates (HIV-1(9466) and HIV-1(CAR402) from AIDS patients in Thailand and Africa), respectively. These four SHIV clones, designated SHIV-A-170, SHIV-A-Q23, SHIV-9466.33, and SHIV-E-CAR, contain envelope (env) genes from the subtype-A or -E viruses. Interestingly, SHIV-A-170, SHIV-A-Q23, and SHIV-9466.33 were restricted for replication in cultures of macaque lymphoid cells, whereas SHIV-E-CAR replicated efficiently in these cells. Additional studies to define the block to replication in macaque cells were focused on the subtype-E clone SHIV-9466.33. A SHIV intragenic env clone, containing sequence-encompassing V1/V2 regions of HIV-1(CAR402) and V3/V4/V5 regions of SHIV-9466.33, infected and replicated in macaque lymphoid cells. These results indicated that the sequence-encompassing V1/V2 region of HIV-1(9466) was responsible for the block of the SHIV-9466.33 replication in macaque cells. Analysis of viral DNA in acutely infected macaque cells revealed that SHIV-9466.33 was blocked at a step at/or before viral DNA synthesis, presumably during the process of virion entry into cells. In a fluorescence-based cell-cell fusion assay, fusion pore formation readily took place in cocultures of cells expressing the SHIV-9466.33 env glycoprotein with macaque T-lymphoid cells. Taken together, these results demonstrated that the block of SHIV-9466.33 replication in macaque cells is at an early step after fusion pore formation but before reverse transcription.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12127782     DOI: 10.1006/viro.2002.1454

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.

Authors:  Mingkui Zhou; Michael Humbert; Muhammad M Mukhtar; Hanna B Scinto; Hemant K Vyas; Samir K Lakhashe; Siddappa N Byrareddy; Gregor Maurer; Swati Thorat; Joshua Owuor; Zhao Lai; Yidong Chen; Anthony Griffiths; Agnès-Laurence Chenine; Sanjeev Gumber; François Villinger; David Montefiori; Ruth M Ruprecht
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

2.  A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection.

Authors:  Daryl Humes; Sandra Emery; Elizabeth Laws; Julie Overbaugh
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

3.  Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cells.

Authors:  Daryl Humes; Julie Overbaugh
Journal:  J Virol       Date:  2011-02-16       Impact factor: 5.103

4.  Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate.

Authors:  Qiang Liu; Yue Li; GuiBo Yang; JieJie Dai; Ruth M Ruprecht; Yiming Shao
Journal:  J Med Primatol       Date:  2011-09-06       Impact factor: 0.667

5.  Vaccination of rhesus macaques with a vif-deleted simian immunodeficiency virus proviral DNA vaccine.

Authors:  Ellen E Sparger; Robert A Dubie; Barbara L Shacklett; Kelly S Cole; W L Chang; Paul A Luciw
Journal:  Virology       Date:  2008-02-07       Impact factor: 3.616

Review 6.  Coreceptor use in nonhuman primate models of HIV infection.

Authors:  Silvana Tasca Sina; Wuze Ren; Cecilia Cheng-Mayer
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.